Related Experiment Video
Updated: Feb 11, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
MiR-760 enhances TRAIL sensitivity in non-small cell lung cancer via targeting the protein FOXA1
Xiang Zhang1, Lei Wang1, Yu Liu1
1Department of Thoracic, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Abstract:
Non-small cell lung cancer (NSCLC) is one of the leading cause of death worldwide. TNF-related apoptosis-inducing ligand (TRAIL) is a promising anti-tumor agent with the ability to kill tumor cells while spare normal ones. MicroRNAs (miRNAs) are small, non-coding RNAs that play vital roles in carcinogenesis. Although miR-760 has been reported to be dysregulated in a variety of cancers, the role of miR-760 in NSCLC is not fully understood, and the relationship between miR-760 dysregulation and TRAIL sensitivity is still elusive. In the current study, we found that miR-760 is significantly downregulated in NSCLC tissues and cell lines. We also found that ectopic expression of miR-760, by targeting the FOXA1, enhanced TRAIL sensitivity in NSCLC cells. Correspondingly, silencing of FOXA1 also sensitized NSCLC cell to TRAIL-induced apoptosis and proliferation inhibition. In summary, these findings suggest that miR-760 should be considered as a tumor suppressor since it negatively regulates the oncogene protein FOXA1 and regulated TRAIL sensitivity in NSCLC cells.
Insights
MicroRNA-760 (miR-760) is downregulated in non-small cell lung cancer (NSCLC). Restoring miR-760 enhances sensitivity to TNF-related apoptosis-inducing ligand (TRAIL) therapy by targeting FOXA1.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
- TNF-related apoptosis-inducing ligand (TRAIL) shows potential as an anti-cancer therapeutic due to its tumor-specific cytotoxicity.
- The role of microRNA-760 (miR-760) in NSCLC and its connection to TRAIL sensitivity are not well-defined.
Purpose of the Study:
- To investigate the expression levels of miR-760 in NSCLC.
- To elucidate the functional role of miR-760 in NSCLC cells.
- To determine the relationship between miR-760, FOXA1, and TRAIL-induced apoptosis in NSCLC.
Main Methods:
- Quantitative real-time PCR to assess miR-760 expression in NSCLC tissues and cell lines.
- Transfection of NSCLC cells with miR-760 mimics or inhibitors.
- Western blotting to analyze FOXA1 protein levels.
- Cell viability assays and apoptosis assays to evaluate TRAIL sensitivity.
Main Results:
- miR-760 was significantly downregulated in NSCLC tissues and cell lines compared to normal controls.
- Ectopic expression of miR-760 enhanced NSCLC cell sensitivity to TRAIL-induced apoptosis.
- miR-760 directly targeted the 3'-untranslated region of FOXA1, leading to reduced FOXA1 expression.
- Silencing FOXA1 mimicked the effect of miR-760, sensitizing NSCLC cells to TRAIL and inhibiting proliferation.
Conclusions:
- miR-760 functions as a tumor suppressor in NSCLC.
- miR-760 enhances TRAIL sensitivity by negatively regulating the oncogene FOXA1.
- These findings highlight miR-760 as a potential therapeutic target for improving TRAIL-based cancer treatments in NSCLC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Lung Capacity
Self-Evaluation: Self-Enhancement and Self-Verification
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Permeability Enhancement

